HER2 in Breast Cancer: A Negative Feedback Loop for Trastuzumab Resistance
This is a new paper indicating that "HER2 overexpression promotes EMT and the emergence of cancer stem cell properties in BC." This in turn "Increased expression and activation of metalloproteinases during EMT leads to proteolytic cleavage and shedding of HER2 receptor, which downregulates HER2 extracellular domain and eventually increases trastuzumab resistance." Therefore, anti cancer stem cell treatments (e.g. most effective may be Salinomycin, but others more accessible like Metformin may also work) may bring back the response to trastuzumab.